Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$4.23 -2.5%	$4.09	$1.00 ▼ $5.87	$38.48M	0.8	143,362 shs	19,818 shs
ENTA Enanta Pharmaceuticals	$7.18 -0.7%	$6.07	$4.09 ▼ $17.24	$154.55M	0.76	285,193 shs	183,679 shs
MOLN Molecular Partners	$3.68 -3.6%	$3.89	$3.36 ▼ $12.22	$154.23M	1.11	15,722 shs	285 shs
SLN Silence Therapeutics	$5.95 +5.1%	$4.46	$1.97 ▼ $22.47	N/A	1.41	303,377 shs	124,769 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	0.00%	-5.45%	+3.33%	+15.12%	+132.09%
ENTA Enanta Pharmaceuticals	0.00%	-2.43%	+19.11%	+14.58%	-38.88%
MOLN Molecular Partners	0.00%	-3.85%	-4.82%	-4.58%	-52.89%
SLN Silence Therapeutics	0.00%	+1.25%	+10.12%	+58.99%	-70.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	1.8348 of 5 stars	3.3	3.0	0.0	0.0	1.7	0.0
ENTA Enanta Pharmaceuticals	3.6957 of 5 stars	3.4	1.0	4.7	2.0	2.5	0.0
MOLN Molecular Partners	2.8574 of 5 stars	3.8	5.0	0.0	0.0	0.0	0.6
SLN Silence Therapeutics	2.8307 of 5 stars	3.4	4.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	183.69% Upside
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	150.70% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	226.00% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	468.63% Upside

Current Analyst Ratings Breakdown

Latest ATHE, ENTA, MOLN, and SLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/13/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
ENTA Enanta Pharmaceuticals	$67.64M	2.27	N/A	N/A	$6.08 per share	1.18
MOLN Molecular Partners	$5.65M	26.31	N/A	N/A	$3.99 per share	0.92
SLN Silence Therapeutics	$43.26M	N/A	N/A	N/A	$4.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	-1,043.01%	-42.20%	-38.12%	8/25/2025 (Estimated)
SLN Silence Therapeutics	-$45.31M	-$1.50	N/A	N/A	N/A	-260.55%	-56.17%	-33.96%	8/15/2025 (Estimated)

Latest ATHE, ENTA, MOLN, and SLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
MOLN Molecular Partners	N/A	15.28	15.28
SLN Silence Therapeutics	N/A	8.81	8.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
ENTA Enanta Pharmaceuticals	94.99%
MOLN Molecular Partners	26.55%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
ENTA Enanta Pharmaceuticals	13.89%
MOLN Molecular Partners	5.93%
SLN Silence Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
SLN Silence Therapeutics	100	N/A	N/A	Not Optionable

ATHE, ENTA, MOLN, and SLN Headlines

Recent News About These Companies

Wall Street Zen Upgrades Silence Therapeutics (NASDAQ:SLN) to "Hold"

June 16, 2025 | americanbankingnews.com

Silence Therapeutics' (SLN) "Buy" Rating Reiterated at Chardan Capital

June 16, 2025 | americanbankingnews.com

Silence Therapeutics' (SLN) "Buy" Rating Reaffirmed at HC Wainwright

June 15, 2025 | americanbankingnews.com

Silence Therapeutics (NASDAQ:SLN) Rating Increased to Hold at Wall Street Zen

June 14, 2025 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Silence Therapeutics (NASDAQ:SLN)

June 13, 2025 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Receives Buy Rating from Chardan Capital

June 13, 2025 | marketbeat.com

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

June 12, 2025 | businesswire.com

Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) PT at $33.83

June 10, 2025 | americanbankingnews.com

Silence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from Analysts

June 7, 2025 | marketbeat.com

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

June 6, 2025 | zacks.com

Silence Therapeutics plc (NASDAQ:SLN) Short Interest Update

June 4, 2025 | marketbeat.com

Millennium Management LLC Reduces Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

June 1, 2025 | marketbeat.com

Silence Therapeutics plc (NASDAQ:SLN) Shares Acquired by Bank of America Corp DE

June 1, 2025 | marketbeat.com

Silence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LP

May 27, 2025 | marketbeat.com

Point72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

May 22, 2025 | marketbeat.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
By Gabriel Osorio-Mazilli | June 6, 2025
View A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
Super Micro Computer Stock's Rally Backed by Strong Financials
By Gabriel Osorio-Mazilli | June 19, 2025
View Super Micro Computer Stock's Rally Backed by Strong Financials
ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly
By Jeffrey Neal Johnson | June 10, 2025
View ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly
Why Analysts Are Bullish on Celsius Stock After 30% Drop
By Gabriel Osorio-Mazilli | June 16, 2025
View Why Analysts Are Bullish on Celsius Stock After 30% Drop

ATHE, ENTA, MOLN, and SLN Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$4.23 -0.11 (-2.53%)

Closing price 03:42 PM Eastern

Extended Trading

$4.23 0.00 (0.00%)

As of 04:04 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Enanta Pharmaceuticals NASDAQ:ENTA

$7.18 -0.05 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$7.18 +0.00 (+0.07%)

As of 04:04 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Molecular Partners NASDAQ:MOLN

$3.68 -0.14 (-3.64%)

Closing price 02:48 PM Eastern

Extended Trading

$4.11 +0.43 (+11.63%)

As of 04:27 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Silence Therapeutics NASDAQ:SLN

$5.96 +0.30 (+5.37%)

As of 04:00 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time